Clinical Trial Results:
An Open-label, Randomized, Phase 3 Trial of intravenous Temsirolimus (CCI-779) at two Dose Levels Compared to Investigator's Choice Therapy in relapsed, Refractory Subjects with Mantle Cell lymphoma (MCL)
Summary
|
|
EudraCT number |
2004-001430-16 |
Trial protocol |
AT SE GB DE IT ES |
Global completion date |
04 Jan 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Mar 2016
|
First version publication date |
11 Feb 2015
|
Other versions |
|
Summary report(s) |
3066K1-305 EU Posting |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.